HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company's HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company's HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company's HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Diagnostic & Testing Equipment
- Sub-Industry: N/A
- Symbol: NASDAQ:HTGM
- CUSIP: N/A
- Web: www.htgmolecular.com
Capitalization:- Market Cap: $21.06 million
- Outstanding Shares: 11,448,000
Average Prices:- 50 Day Moving Avg: $1.87
- 200 Day Moving Avg: $1.87
- 52 Week Range: $1.20 - $4.45
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.07
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $5.5 million
- Price / Sales: 3.83
- Book Value: ($0.14) per share
- Price / Book: -13.14
Profitability:- EBIDTA: ($20,910,000.00)
- Net Margins: -432.74%
- Return on Equity: -1,538.49%
- Return on Assets: -131.17%
Debt:- Debt-to-Equity Ratio: -1.44%
- Current Ratio: 1.58%
- Quick Ratio: 1.46%
Misc:- Average Volume: 397,629 shs.
- Beta: 0.61
- Short Ratio: 4.82
Frequently Asked Questions for HTG Molecular Diagnostics (NASDAQ:HTGM)
What is HTG Molecular Diagnostics' stock symbol?
HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."
How were HTG Molecular Diagnostics' earnings last quarter?
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.60) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.60). The company had revenue of $1.76 million for the quarter, compared to analyst estimates of $1.80 million. HTG Molecular Diagnostics had a negative net margin of 432.74% and a negative return on equity of 1,538.49%. View HTG Molecular Diagnostics' Earnings History.
When will HTG Molecular Diagnostics make its next earnings announcement?
Where is HTG Molecular Diagnostics' stock going? Where will HTG Molecular Diagnostics' stock price be in 2017?
3 brokerages have issued twelve-month price objectives for HTG Molecular Diagnostics' stock. Their predictions range from $6.00 to $6.50. On average, they anticipate HTG Molecular Diagnostics' stock price to reach $6.17 in the next twelve months. View Analyst Ratings for HTG Molecular Diagnostics.
What are analysts saying about HTG Molecular Diagnostics stock?
Here are some recent quotes from research analysts about HTG Molecular Diagnostics stock:
- 1. According to Zacks Investment Research, "HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. " (8/15/2017)
- 2. HC Wainwright analysts commented, "We note that the launch of this new assay comes on schedule and expands the company’s existing menu following the launch of HTG EdgeSeq EGFR, KRAS and BRAF Mutation Assays for research use. Investors may recall that this assay was designed for retrospective gene expression profiling (GEP) to complement traditional immunohistochemistry (IHC) testing, allowing investigators to assess mRNA expression of large numbers of biomarkers—up to 470 mRNA targets in this case—when formalin-fixed, paraffin-embedded (FFPE) sample availability is limited. Importantly, small and minimally invasive tissue biopsies are the trend nowadays in diagnostics, and within this setting, EdgeSeq PATH Assay allows for a more comprehensive profiling than conventional IHC. This may potentially lead to new GEP-based diagnostic or prognostic tests in oncology and beyond, in our view." (6/29/2017)
Who are some of HTG Molecular Diagnostics' key competitors?
Some companies that are related to HTG Molecular Diagnostics include Inotek Pharmaceuticals Corporation (ITEK), Histogenics Corporation (HSGX), Catabasis Pharmaceuticals (CATB), Bellerophon Therapeutics (BLPH), Bio-Path Holdings (BPTH), Aptose Biosciences (APTO), Viking Therapeutics (VKTX), Zosano Pharma Corporation (ZSAN), OmniComm Systems (OMCM), Aradigm Corporation (ARDM), Prima BioMed Ltd (PBMD), Biocept (BIOC), Cleveland BioLabs (CBLI), Egalet Corporation (EGLT), Auris Medical Holding AG (EARS), Cesca Therapeutics (KOOL), Tokai Pharmaceuticals (NVUS) and AEterna Zentaris (AEZS).
Who are HTG Molecular Diagnostics' key executives?
HTG Molecular Diagnostics' management team includes the folowing people:
- Ann F. Hanham Ph.D., Independent Chairman of the Board
- Timothy B. Johnson, President, Chief Executive Officer, Director
- Shaun D. McMeans, Vice President of Finance and Administration, Chief Financial Officer
- Patrick C. Roche Ph.D., Senior Vice President - Research and Product Development
- Debra A. Gordon Ph.D. J.D., Vice President, Chief Legal Counsel and Secretary
- John L. Lubniewski, Chief Business Officer
- Donnie M. Hardison, Director
- Harry A. George, Independent Director
- James T. LaFrance, Independent Director
- Lee Roy McCracken, Independent Director
When did HTG Molecular Diagnostics IPO?
(HTGM) raised $50 million in an IPO on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.
Who owns HTG Molecular Diagnostics stock?
HTG Molecular Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include
NOVO HOLDINGS A
(12.03%),
NOVO HOLDINGS A
(10.50%),
GLAXOSMITHKLINE PLC
(8.30%),
GLAXOSMITHKLINE PLC
(6.90%), FMR LLC (7.07%) and Vanguard Group Inc. (1.42%). Company insiders that own HTG Molecular Diagnostics stock include Debra A Gordon, Holdings A/S Novo, John L Lubniewski, Patrick C Roche, Plc Glaxosmithkline, Shaun D Mcmeans and Tim B Johnson. View Institutional Ownership Trends for HTG Molecular Diagnostics.
Who bought HTG Molecular Diagnostics stock? Who is buying HTG Molecular Diagnostics stock?
How do I buy HTG Molecular Diagnostics stock?
Shares of HTG Molecular Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is HTG Molecular Diagnostics' stock price today?
One share of HTG Molecular Diagnostics stock can currently be purchased for approximately $1.84.
MarketBeat Community Rating for HTG Molecular Diagnostics (NASDAQ HTGM)MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for HTG Molecular Diagnostics (NASDAQ:HTGM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $6.17 (235.14% upside) |
Analysts' Ratings History for HTG Molecular Diagnostics (NASDAQ:HTGM)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/12/2017 | HC Wainwright | Reiterated Rating | Buy | $6.00 | High |  |
| 5/16/2017 | Rodman & Renshaw | Boost Price Target | Buy -> Buy | $4.50 -> $6.00 | High | |
| 4/19/2017 | Canaccord Genuity | Boost Price Target | Hold | $5.50 -> $6.50 | Low | |
| 3/28/2016 | Leerink Swann | Reiterated Rating | Outperform | $10.00 -> $5.00 | N/A | |
(Data available from 9/24/2015 forward)
Earnings History for HTG Molecular Diagnostics (NASDAQ:HTGM)Earnings History by Quarter for HTG Molecular Diagnostics (NASDAQ HTGM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/13/2017 | | ($0.53) | | | | | N/A | |
| 8/8/2017 | Q2 | ($0.60) | ($0.60) | $1.80 million | $1.76 million | View | Listen | |
| 5/15/2017 | Q1 | ($0.58) | ($0.73) | $2.44 million | $1.37 million | View | N/A | |
| 11/14/2016 | Q3 2016 | ($0.87) | ($0.92) | $2.05 million | $0.91 million | View | Listen | |
| 8/9/2016 | Q2 | ($0.95) | ($0.98) | | $1.90 million | View | Listen | |
| 5/12/2016 | Q1 | ($0.83) | ($1.02) | $1.23 million | $0.87 million | View | Listen | |
| 3/24/2016 | Q4 | ($0.79) | ($0.83) | $1.31 million | $1.22 million | View | Listen | |
| 11/12/2015 | Q315 | ($0.85) | ($0.76) | $1.07 million | $1.00 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.71) | ($1.73) | $1.01 million | $0.79 million | View | Listen | |
| 6/1/2015 | Q115 | | ($14.99) | | $1.00 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for HTG Molecular Diagnostics (NASDAQ:HTGM)Current Year EPS Consensus Estimate: $-2.29 EPS
Next Year EPS Consensus Estimate: $-1.72 EPS
Dividend History for HTG Molecular Diagnostics (NASDAQ:HTGM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for HTG Molecular Diagnostics (NASDAQ:HTGM)Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 21.67%
Insider Trades by Quarter for HTG Molecular Diagnostics (NASDAQ:HTGM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/25/2017 | Holdings A/S Novo | Major Shareholder | Sell | 1,149,813 | $1.81 | $2,081,161.53 | |
| 8/24/2017 | Holdings A/S Novo | Major Shareholder | Sell | 382,437 | $1.91 | $730,454.67 | |
| 8/23/2017 | Holdings A/S Novo | Major Shareholder | Sell | 47,162 | $2.02 | $95,267.24 | |
| 8/22/2017 | Holdings A/S Novo | Major Shareholder | Sell | 80,586 | $2.07 | $166,813.02 | |
| 3/27/2017 | Plc Glaxosmithkline | Insider | Sell | 300,000 | $10.15 | $3,045,000.00 | |
| 4/4/2016 | Debra A Gordon | VP | Sell | 1,672 | $2.89 | $4,832.08 | |
| 4/4/2016 | John L Lubniewski | Insider | Sell | 796 | $2.89 | $2,300.44 | |
| 4/4/2016 | Shaun D Mcmeans | CFO | Sell | 1,601 | $2.89 | $4,626.89 | |
| 4/4/2016 | Tim B Johnson | CEO | Sell | 4,914 | $2.89 | $14,201.46 | |
| 3/14/2016 | Debra A Gordon | VP | Sell | 5,535 | $2.38 | $13,173.30 | |
| 3/14/2016 | John L Lubniewski | Insider | Sell | 6,889 | $2.38 | $16,395.82 | |
| 3/14/2016 | Patrick C Roche | SVP | Sell | 5,929 | $2.38 | $14,111.02 | |
| 3/14/2016 | Shaun D Mcmeans | CFO | Sell | 5,651 | $2.38 | $13,449.38 | |
| 3/14/2016 | Tim B Johnson | CEO | Sell | 10,621 | $2.38 | $25,277.98 | |
| 3/9/2016 | Debra A Gordon | VP | Sell | 3,256 | $2.69 | $8,758.64 | |
| 3/9/2016 | John L Lubniewski | Insider | Sell | 4,067 | $2.69 | $10,940.23 | |
| 3/9/2016 | Patrick C Roche | SVP | Sell | 3,491 | $2.69 | $9,390.79 | |
| 3/9/2016 | Shaun D Mcmeans | CFO | Sell | 3,325 | $2.69 | $8,944.25 | |
| 3/9/2016 | Tim B Johnson | CEO | Sell | 6,299 | $2.69 | $16,944.31 | |
| 8/24/2015 | Debra A Gordon | VP | Buy | 1,000 | $5.16 | $5,160.00 | |
| 8/18/2015 | Patrick C. Roche | SVP | Buy | 6,500 | $5.76 | $37,440.00 | |
| 8/11/2015 | John L Lubniewski | Insider | Buy | 5,000 | $7.67 | $38,350.00 | |
| 5/11/2015 | A/S Novo | Major Shareholder | Buy | 365,106 | $14.00 | $5,111,484.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for HTG Molecular Diagnostics (NASDAQ:HTGM)
Latest Headlines for HTG Molecular Diagnostics (NASDAQ:HTGM)
| Source: |
|
| Date | Headline |
|---|
 | Should You Have HTG Molecular Diagnostics Inc’s (HTGM) In Your Portfolio?
finance.yahoo.com - September 23 at 9:36 AM |
 | HTG Molecular Diagnostics (HTGM) Says it Was Issued Two Method ... - StreetInsider.com
www.streetinsider.com - September 20 at 8:22 PM |
| HTG Announces Issuance of Two Method Patents Related to its Technology
finance.yahoo.com - September 20 at 8:22 PM |
| HTG Molecular Diagnostics (HTGM) Granted ISO 13485 Certification for Health Canada CMDCAS Requirements - StreetInsider.com
www.streetinsider.com - September 20 at 12:41 AM |
| HTG Molecular Diagnostics (HTGM) Granted ISO 13485 Certification for Health Canada CMDCAS Requirements
www.streetinsider.com - September 19 at 7:40 PM |
 | BRIEF-HTG Molecular Diagnostics receives ISO 13485 certification for Health Canada CMDCAS requirements
www.reuters.com - September 18 at 7:07 PM |
| HTG Molecular Diagnostics Receives ISO 13485 Certification for Health Canada CMDCAS Requirements
finance.yahoo.com - September 18 at 7:06 PM |
 | HTG Molecular Diagnostics' (HTGM) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - September 17 at 10:58 PM |
 | 22 Stocks Moving In Thursday's Pre-Market Session | Benzinga - Benzinga
www.benzinga.com - September 14 at 9:55 PM |
 | HTG Molecular Diagnostics Provides Regulatory Update for its HTG EdgeSeq ALKPlus Assay - GlobeNewswire (press release)
globenewswire.com - September 12 at 1:10 AM |
| HTG Molecular Diagnostics Provides Regulatory Update for its HTG EdgeSeq ALKPlus Assay
finance.yahoo.com - September 11 at 8:07 PM |
 | HTG Molecular Diagnostics to Present at the Rodman & Renshaw 19th Annual Investment Conference - Nasdaq
www.nasdaq.com - September 7 at 12:37 AM |
| HTG Molecular Diagnostics to Present at the Rodman & Renshaw 19th Annual Investment Conference
finance.yahoo.com - September 6 at 7:36 PM |
| HTG Molecular Diagnostics, Inc. (HTGM) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - September 3 at 9:06 AM |
| ETFs with exposure to HTG Molecular Diagnostics, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 7:34 PM |
| HTG Molecular Diagnostics, Inc. (HTGM) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - August 27 at 1:44 PM |
| HTG Molecular Diagnostics, Inc. :HTGM-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 5:57 AM |
| Insider Selling: HTG Molecular Diagnostics Inc (HTGM) Major Shareholder Sells 47,162 Shares of Stock
www.americanbankingnews.com - August 25 at 10:28 PM |
| Holdings A/S Novo Sells 1,149,813 Shares of HTG Molecular Diagnostics Inc (HTGM) Stock
www.americanbankingnews.com - August 25 at 10:28 PM |
| Holdings A/S Novo Sells 382,437 Shares of HTG Molecular Diagnostics Inc (HTGM) Stock
www.americanbankingnews.com - August 25 at 10:28 PM |
| HTG Molecular Diagnostics, Inc. (HTGM) Major Shareholder Sells $166,813.02 in Stock
www.americanbankingnews.com - August 22 at 10:20 PM |
| Contrasting Varex Imaging (VREX) and HTG Molecular Diagnostics (HTGM)
www.americanbankingnews.com - August 21 at 10:22 PM |
| HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Short Interest Update
www.americanbankingnews.com - August 13 at 2:20 AM |
| HTG Molecular Diagnostics, Inc. (HTGM) Lifted to Sell at ValuEngine
www.americanbankingnews.com - August 12 at 8:20 PM |
| Reviewing HTG Molecular Diagnostics (NASDAQ:HTGM) and VAREX IMAGING (VREX)
www.americanbankingnews.com - August 12 at 12:12 PM |
| HTG Molecular Diagnostics' Technology to be Used in WIN Consortium NSCLC Clinical Trial - GlobeNewswire (press release)
globenewswire.com - August 9 at 7:53 PM |
| HTG Molecular Diagnostics’ Technology to be Used in WIN Consortium NSCLC Clinical Trial
finance.yahoo.com - August 9 at 7:53 PM |
| Edited Transcript of HTGM earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 7:53 PM |
| HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Announces Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - August 9 at 7:48 PM |
 | HTG Molecular Diagnostics' (HTGM) CEO T. J. Johnson on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 12:18 AM |
| HTG Molecular Diagnostics Reports Second Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - August 8 at 7:17 PM |
| HTG Molecular Diagnostics Reports Second Quarter 2017 Results
finance.yahoo.com - August 8 at 7:17 PM |
| ETFs with exposure to HTG Molecular Diagnostics, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 12:45 AM |
| Head to Head Survey: Cepheid (CPHD) and HTG Molecular Diagnostics (NASDAQ:HTGM)
www.americanbankingnews.com - July 31 at 9:33 AM |
| HTG Molecular Diagnostics, Inc. (HTGM) Given a $6.00 Price Target at HC Wainwright
www.americanbankingnews.com - July 30 at 1:30 PM |
| HTG Molecular Diagnostics, Inc. (HTGM) Short Interest Up 46.3% in July
www.americanbankingnews.com - July 29 at 7:01 AM |
| HTG Molecular Diagnostics (HTGM) Reports Second Companion Diagnostic Development Project with QIAGEN (QGEN)
www.streetinsider.com - July 29 at 3:40 AM |
| HTG Molecular Diagnostics (HTGM) Reports Second Companion ... - StreetInsider.com
www.streetinsider.com - July 27 at 8:16 PM |
| HTG Molecular Diagnostics Announces Second Companion Diagnostic Development Project with QIAGEN
finance.yahoo.com - July 27 at 8:16 PM |
| HTG Molecular Diagnostics to Present at the Canaccord Genuity Growth Conference
finance.yahoo.com - July 26 at 9:04 PM |
| HTG Molecular Diagnostics to Hold 2017 Second Quarter Financial ... - Nasdaq
www.nasdaq.com - July 19 at 8:15 PM |
| HTG Molecular Diagnostics to Hold 2017 Second Quarter Financial Results Conference Call on August 8, 2017 - GlobeNewswire (press release)
globenewswire.com - July 19 at 7:14 AM |
| HTG Molecular Diagnostics Has Its Own Niche
seekingalpha.com - July 18 at 9:56 PM |
| HTG Molecular Diagnostics to Hold 2017 Second Quarter Financial Results Conference Call on August 8, 2017
feeds.benzinga.com - July 18 at 4:34 PM |
| Head-To-Head Review: WaferGen Bio-systems (WGBS) and HTG Molecular Diagnostics (NASDAQ:HTGM)
www.americanbankingnews.com - July 17 at 12:18 AM |
| HTG Molecular Diagnostics, Inc. (HTGM) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - July 8 at 11:26 PM |
| HTG Molecular Diagnostics Launches its HTG EdgeSeq PATH Assay - Nasdaq
www.nasdaq.com - June 30 at 7:45 PM |
| HC Wainwright Reaffirms Buy Rating for HTG Molecular Diagnostics, Inc. (HTGM)
www.americanbankingnews.com - June 29 at 8:16 AM |
| HTG Molecular Diagnostics Launches its HTG EdgeSeq PATH ... - GlobeNewswire (press release)
globenewswire.com - June 29 at 12:15 AM |
| BRIEF-HTG Molecular Diagnostics has launched new HTG EdgeSeq PATH Assay
www.reuters.com - June 28 at 7:10 PM |
HTG Molecular Diagnostics (HTGM) Chart for Sunday, September, 24, 2017
